Jennison Associates LLC Biomarin Pharmaceutical Inc Transaction History

Jennison Associates LLC

$155 Billion
Q2 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	SELL	$76.22 - $98.51 $19.6 Million - $25.3 Million	-257,326 Reduced 43.66%	332,018 $32 Million
Q3 2023 Oct 31, 2023	BUY	$85.07 - $94.48 $35 Million - $38.9 Million	411,543 Added 231.46%	589,344 $52.1 Million
Q2 2023 Aug 03, 2023	SELL	$86.68 - $100.3 $43 Million - $49.8 Million	-496,307 Reduced 73.62%	177,801 $15.4 Million
Q1 2023 Apr 26, 2023	BUY	$87.74 - $117.27 $8.38 Million - $11.2 Million	95,485 Added 16.5%	674,108 $65.6 Million
Q4 2022 Feb 09, 2023	BUY	$80.93 - $108.63 $1.22 Million - $1.64 Million	15,117 Added 2.68%	578,623 $59.9 Million
Q3 2022 Nov 01, 2022	SELL	$82.16 - $96.94 $13.6 Million - $16.1 Million	-165,664 Reduced 22.72%	563,506 $47.8 Million
Q2 2022 Aug 02, 2022	BUY	$71.48 - $86.85 $1.62 Million - $1.97 Million	22,642 Added 3.2%	729,170 $60.4 Million
Q1 2022 May 11, 2022	BUY	$74.28 - $92.69 $11.4 Million - $14.3 Million	153,984 Added 27.87%	706,528 $54.5 Million
Q4 2021 Feb 08, 2022	BUY	$71.72 - $91.47 $39.6 Million - $50.5 Million	552,544 New	552,544 $48.8 Million
Q1 2021 May 11, 2021	SELL	$74.73 - $90.69 $33.9 Million - $41.2 Million	-453,994 Closed	0 $0
Q4 2020 Feb 05, 2021	SELL	$72.61 - $90.2 $14.4 Million - $17.9 Million	-198,798 Reduced 30.45%	453,994 $39.8 Million
Q3 2020 Nov 04, 2020	SELL	$71.87 - $131.03 $499 Million - $909 Million	-6,937,973 Reduced 91.4%	652,792 $49.7 Million
Q2 2020 Aug 06, 2020	SELL	$79.55 - $124.22 $49.6 Million - $77.5 Million	-623,698 Reduced 7.59%	7,590,765 $936 Million
Q1 2020 May 06, 2020	BUY	$71.37 - $96.85 $83.8 Million - $114 Million	1,174,290 Added 16.68%	8,214,463 $694 Million
Q4 2019 Feb 07, 2020	SELL	$64.27 - $86.37 $83 Million - $112 Million	-1,291,227 Reduced 15.5%	7,040,173 $595 Million
Q3 2019 Nov 08, 2019	SELL	$67.4 - $85.11 $75.2 Million - $95 Million	-1,116,415 Reduced 11.82%	8,331,400 $562 Million
Q2 2019 Aug 06, 2019	SELL	$80.35 - $93.9 $238 Million - $278 Million	-2,964,778 Reduced 23.89%	9,447,815 $0
Q1 2019 May 10, 2019	BUY	$84.2 - $98.62 $68.4 Million - $80.1 Million	812,133 Added 7.0%	12,412,593 $1.1 Billion
Q4 2018 Feb 06, 2019	BUY	$80.14 - $106.07 $60.6 Million - $80.2 Million	756,222 Added 6.97%	11,600,460 $988 Million
Q3 2018 Nov 08, 2018	SELL	$93.92 - $105.72 $69.9 Million - $78.7 Million	-744,393 Reduced 6.42%	10,844,238 $1.05 Billion
Q2 2018 Aug 02, 2018	SELL	$76.01 - $99.03 $13.2 Million - $17.3 Million	-174,192 Reduced 1.48%	11,588,631 $1.09 Billion
Q1 2018 Apr 20, 2018	SELL	$77.67 - $92.63 $3.64 Million - $4.34 Million	-46,872 Reduced 0.4%	11,762,823 $954 Million
Q4 2017 Jan 25, 2018	SELL	$80.76 - $95.13 $40.8 Million - $48 Million	-504,662 Reduced 4.1%	11,809,695 $1.05 Billion
Q3 2017 Nov 03, 2017	BUY	$80.6 - $94.95 $993 Million - $1.17 Billion	12,314,357	12,314,357 $1.15 Billion

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

Black Rock Inc. New York, NY

22.7M
Shares

$1.6 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19M
Shares

$1.34 Billion
0.03% of portfolio
Primecap Management CO Pasadena, CA

18.8M
Shares

$1.33 Billion
1.14% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$983 Million
0.72% of portfolio
Capital Research Global Investors Los Angeles, CA

9.69M
Shares

$684 Million
0.18% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.

Account